体外式膜型人工肺（ECMO）装置の世界市場：洞察、競合情勢、市場予測：2028年

世界の体外式膜型人工肺（ECMO）装置の市場規模は、2023年から2028年の予測期間中に4.1％のCAGRで成長すると予測されています。体外式膜型人工肺（ECMO）装置の需要は、慢性呼吸器疾患や心臓疾患における長期的な循環サポートの必要性の高まり、患者の転帰改善につながる技術進歩の高まり、体外膜酸素療法装置の採用増加によって後押しされており、プロセス中の潜在的な課題を排除するための主要企業による新技術の導入、不健康な習慣の増加、肺疾患や心臓疾患に罹患している大規模な患者プール、製品の発売と承認の増加などが、2023年から2028年までの予測期間中に同市場の全体的な成長に寄与しています。

体外式膜型人工肺（ECMO）装置市場は、さまざまな要因によって製品需要が伸びていますが、主要な要因の1つは、心臓疾患や呼吸器疾患の発生率の増加です。ECMOシステムは長期の呼吸不全や心肺不全に使用され、6時間以上にわたって患者の血液の体外循環と生理的ガス交換を補助します。虚血性心疾患（IHD）は冠動脈疾患（CAD）およびアテローム性動脈硬化性心血管疾患（ACD）とも呼ばれ、世界的に主要な死因となっています。このような患者は心臓血管手術中に人工的なサポートを必要とし、ECMO市場の需要を牽引しています。

したがって、上記の要因が2023年～2028年の予測期間中の体外式膜型人工肺（ECMO）装置市場の成長に寄与しています。

しかし、感染症、技術的失敗、出血、装置に関する厳しい規制承認など、ECMO装置に関連する合併症は、体外式膜型人工肺（ECMO）装置市場の成長を制限する可能性があります。

当レポートでは、世界の体外式膜型人工肺（ECMO）装置市場について調査し、市場の概要とともに、マシンモダリティ別、患者タイプ別、用途別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 体外式膜型人工肺（ECMO）装置市場レポートのイントロダクション

第2章 体外式膜型人工肺（ECMO）装置市場のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 体外式膜型人工肺（ECMO）装置市場の主要な要因分析

• 体外式膜型人工肺（ECMO）装置市場の促進要因
• 体外式膜型人工肺（ECMO）装置市場の抑制要因と課題
• 体外式膜型人工肺（ECMO）装置市場の機会

第5章 体外式膜型人工肺（ECMO）装置市場におけるポーターのファイブフォース分析

第6章 体外式膜型人工肺（ECMO）装置市場の概要

• マシンモダリティ別
• 患者タイプ別
• 用途別
• 地域別

第7章 体外式膜型人工肺（ECMO）装置市場における企業と製品プロファイル

• Getinge Group
• Medtronic
• LivaNova PLC
• XENIOS AG
• Terumo Corporation
• MicroPort Scientific Corporation
• NIPRO Corporation
• OriGen Biomedical, Inc.
• EUROSETS S.r.l.
• ALung Technologies, Inc.
• Medos Medizintechnik AG
• Abiomed
• Novalung
• Senko Medical Instrument Manufacturing Co. Ltd.
• Braile Biomedica Ltd.
• Sorin
• Thoratec Corporation
• MAQUET Holding B.V. & Co. KG.
• Tianjin Medical
• SHANDONG WEGO NEW LIFE MEDICAL DEVICES CO., LTD.

第8章 KOL の見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightについて

第11章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Global (2020-2028)
• Table 3: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Global by Machine Modality (2020-2028)
• Table 4: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Global by Patient Type (2020-2028)
• Table 5: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Global by Application (2020-2028)
• Table 6: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Global by Geography (2020-2028)
• Table 7: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in North America (2020-2028)
• Table 8: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in the US (2020-2028)
• Table 9: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Canada (2020-2028)
• Table 10: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Mexico (2020-2028)
• Table 11: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Europe (2020-2028)
• Table 12: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in France (2020-2028)
• Table 13: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Germany (2020-2028)
• Table 14: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in the United Kingdom (2020-2028)
• Table 15: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Italy (2020-2028)
• Table 16: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Spain (2020-2028)
• Table 17: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in the Rest of Europe (2020-2028)
• Table 18: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Asia-Pacific (2020-2028)
• Table 19: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in China (2020-2028)
• Table 20: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Japan (2020-2028)
• Table 21: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in India (2020-2028)
• Table 22: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Australia (2020-2028)
• Table 23: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in South Korea (2020-2028)
• Table 24: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Rest of Asia-Pacific (2020-2028)
• Table 25: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in the Rest of the World (2020-2028)
• Table 26: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in the Middle East (2020-2028)
• Table 27: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Africa (2020-2028)
• Table 28: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in South America (2020-2028)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Global (2020-2028)
• Figure 3: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Global by Machine Modality (2020-2028)
• Figure 4: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Global by Patient Type (2020-2028)
• Figure 5: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Global by Application (2020-2028)
• Figure 6: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Global by Geography (2020-2028)
• Figure 7: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in North America (2020-2028)
• Figure 9: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in the US (2020-2028)
• Figure 10: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Canada (2020-2028)
• Figure 11: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Mexico (2020-2028)
• Figure 12: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Europe (2020-2028)
• Figure 13: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in France (2020-2028)
• Figure 14: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Germany (2020-2028)
• Figure 15: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in the United Kingdom (2020-2028)
• Figure 16: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Italy (2020-2028)
• Figure 17: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Spain (2020-2028)
• Figure 18: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in the Rest of Europe (2020-2028)
• Figure 19: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Asia-Pacific (2020-2028)
• Figure 20: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in China (2020-2028)
• Figure 21: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Japan (2020-2028)
• Figure 22: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in India (2020-2028)
• Figure 23: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Australia (2020-2028)
• Figure 24: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in South Korea (2020-2028)
• Figure 25: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Rest of Asia-Pacific (2020-2028)
• Figure 26: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in the Rest of the World (2020-2028)
• Figure 27: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in the Middle East (2020-2028)
• Figure 28: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in Africa (2020-2028)
• Figure 29: Extracorporeal Membrane Oxygenation (ECMO) Devices Market in South America (2020-2028)
• Figure 30: Market Drivers
• Figure 31: Market Barriers
• Figure 32: Marker Opportunities
• Figure 33: PORTER'S Five Force Analysis

Extracorporeal Membrane Oxygenation (Ecmo) Devices Market By Machine Modality (Veno-Arterial, Veno-Venous, And Arterio-Venous), By Patient Type (Pediatric And Adult), By Application (Respiratory, Cardiac, And Others), and geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing incidence of cardiopulmonary disease and respiratory failure and the growing demand of portable ecmo devices across the globe.

The global extracorporeal membrane oxygenation (ECMO) devices market is estimated to grow at a CAGR of 4.1% during the forecast period from 2023 to 2028. The demand for extracorporeal membrane oxygenation (ECMO) devices is being boosted by the growing need for long-term circulatory support in chronic respiratory and cardiac disorders, rising technological advancements leading to improved patient outcomes, increasing adoption of extracorporeal membrane oxygenation machines, introduction of emerging technologies by key players to eliminate potential challenges during the process, rising adoption unhealthy habits, large patient pool suffering from lung and heart diseases, rising product launches and approvals, among others are thereby contributing to the overall growth of the extracorporeal membrane oxygenation (ECMO) devices market during the forecast period from 2023-2028.

Extracorporeal Membrane Oxygenation (ECMO) Devices Market Dynamics:

The extracorporeal membrane oxygenation (ECMO) devices market is witnessing a growth in product demand owing to various factors, one of the key factors being the increasing incidence of heart and respiratory disease.

ECMO systems are used for long-term respiratory or cardiopulmonary failure and provide assisted extracorporeal circulation and physiologic gas exchange of the patient's blood for more than six hours.

Ischemic heart disease (IHD), also referred to as coronary artery disease (CAD) and atherosclerotic cardiovascular disease (ACD) is a leading cause of death worldwide. According to the Global Epidemiology of Ischemic Heart Disease study (2020), every year, globally, IHD affects around 126 million individuals (1,655 per 100,000), which is approximately 1.72% of the world's population. These patients require artificial support during cardiovascular surgery driving the demand for ECMO market.

Further, as per the data from the British Heart Foundation 2023, around 620 million people were living with heart and circulatory diseases across the world, in 2022. According to World Health Organization (WHO) 2021, approximately 17.9 million people died from cardiovascular diseases, which is an estimated 31% of all deaths worldwide in 2021. By 2030, around 23.6 million people are expected to die due to cardiovascular disorders.

As per the data of the World Health Organization (2021), about 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide. A long-term, effective ECMO solution gives critically-ill patients the time and support needed to heal, driving the demand for the extracorporeal membrane oxygenation machine in patients of all ages.

Further, in 2021, more than 33,000 children patients got ECMO support worldwide, according to the latest data available from Extracorporeal Life Support Organization (ELSO) registry. Also, the number of hospitals offering ECMO services reached 264 in 2019 up from 108 in 2008. The usage of ECMO machines has become more widespread over time. ECMO machines were formerly solely used in cases of circulatory or respiratory failure, but now they are also used in cases of heart failure, sepsis, and post-organ transplantation.

Therefore, the above-mentioned factors are contributing to the growth of the extracorporeal membrane oxygenation (ECMO) devices market during the forecast period from 2023-2028.

However, complications associated with ECMO machines, such as infections, technical failure, bleeding, stringent regulatory approvals about the device, and others may restrict the extracorporeal membrane oxygenation (ECMO) devices market growth.

Extracorporeal Membrane Oxygenation (ECMO) Devices Market Segment Analysis:

Extracorporeal Membrane Oxygenation (ECMO) Devices Market by Machine Modality (Veno-Arterial, Veno-Venous, and Arterio-Venous), Patient Type (Pediatric and Adult), Application (Respiratory, Cardiac, and Others), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World)

In the application segment of the extracorporeal membrane oxygenation (ECMO) devices market, the respiratory category is expected to amass a significant revenue share in the year 2022. This can be attributed to the high prevalence of respiratory disease driving the demand for ECMO for the treatment or management of respiratory diseases.

Asthma is one of the major non-communicable diseases. It is a chronic disease of the air passages of the lungs which inflames and narrows them. According to a World Health Organization (WHO) 2021 report, approximately 262 million people in 2019 were suffering from asthma globally. Annually, it has been estimated that 15 million disability-adjusted life-years are lost and 250,000 asthma deaths are reported worldwide.

According to the Extracorporeal Life Support Organization (ELSO), the technique was used to save up to half of the seriously ill COVID-19 patients for whom ventilation isn't working. It was noticed that 55% of the COVID-19 patients who had been placed on ECMO had subsequently survived the condition of patients for whom no other treatment was working.

The great majority of COVID-19 patients needing ECMO were supported using veno-venous (V-V) ECMO for acute respiratory distress syndrome (ARDS).

Further, in November 2022, LivaNova PLC received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S. Food and Drug Administration (FDA) for LifeSPARC™, the Company's next-generation Advanced Circulatory Support (ACS) pump and controller system. It is intended for use in adult patients with acute respiratory failure.

Thus, the above-mentioned factors are likely to propel the demand for the respiratory segment, thereby contributing to the growth of the extracorporeal membrane oxygenation (ECMO) devices market during the forecast period from 2023-2028.

North America is expected to dominate the overall Extracorporeal Membrane Oxygenation (ECMO) Devices Market:

Among all the regions, North America is estimated to account for the largest share in the extracorporeal membrane oxygenation (ECMO) devices market in the year 2022. This domination is due to the growing prevalence of cardiovascular and pulmonary diseases, the growing geriatric population, the introduction of many products, and others in the region.

COVID-19 also boosted the demand for compact cardiopulmonary bypass systems and in October 2020, Abiomed announced that its compact cardiopulmonary bypass system, Breethe OXY-1, received 510(k) clearance from the FDA. This launch boosted the ECMO market in the US and help the company to gain market share.

Further, according to the Centers for Disease Control and Prevention (CDC) 2022, more than 795,000 people in the United States suffer from a stroke every year. As per the same source, approximately 200,000 coronary artery bypass graft surgeries take place each year in the US and are the most commonly performed cardiac procedure. Henceforth, treatment requires extracorporeal membrane oxygenation machines, such as heart-lung machines and oxygenators.

Further, in October 2020, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Abiomed for an all-in-one, compact extracorporeal membrane oxygenation (ECMO) cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System.

Thus, all the above-mentioned factors will lead to an increase in the North America extracorporeal membrane oxygenation (ECMO) devices market growth during the forecasting period of 2023-2028.

Extracorporeal Membrane Oxygenation (ECMO) Devices Market Key Players:

Some of the key market players operating in the extracorporeal membrane oxygenation (ECMO) devices market include: Getinge Group, Medtronic, LivaNova PLC, XENIOS AG, Terumo Corporation, MicroPort Scientific Corporation, NIPRO Corporation, OriGen Biomedical, Inc., EUROSETS S.r.l., Alung Technologies, Inc., Medos Medizintechnik AG, Abiomed, Novalung, Senko Medical Instrument Manufacturing Co. Ltd., Braile Biomedica Ltd., Sorin, Thoratec Corporation, MAQUET Holding B.V. & Co. KG., Tianjin Medical, SHANDONG WEGO NEW LIFE MEDICAL DEVICES CO., LTD., and others.

Recent Developmental Activities in the Extracorporeal Membrane Oxygenation (ECMO) Devices Market:

• In August 2022, AirECMO, Inc., a division of Keystone Perfusion Services, announced a strategic partnership with industry-leading air ambulance provider, REVA, to provide ECMO transportation capabilities globally.
• In July 2022, Inspira™ Technologies launched the Liby System, an advanced form of life support better known by the medical industry as extracorporeal membrane oxygenation (ECMO), used to treat patients with life-threatening heart and lung failure.
• In April 2020, the U.S. Food and Drug Administration (FDA) issued guidance to provide a policy to help expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19, SARS-CoV-2) public health emergency.
• In April 2020, Abiomed acquired Breethe, the developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed's product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation, including patients suffering from cardiogenic shock or respiratory failure such as due to ARDS, H1N1, SARS, or COVID-19.

Key Takeaways from the Extracorporeal Membrane Oxygenation (ECMO) Devices Market Report Study:

• Market size analysis for current extracorporeal membrane oxygenation (ECMO) devices market size (2022), and market forecast for 5 years (2023-2028)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global extracorporeal membrane oxygenation (ECMO) devices market.
• Various opportunities available for the other competitor in the extracorporeal membrane oxygenation (ECMO) devices market space.
• What are the top-performing segments in 2022? How these segments will perform in 2028.
• Which are the top-performing regions and countries in the current extracorporeal membrane oxygenation (ECMO) devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for extracorporeal membrane oxygenation (ECMO) devices market growth in the coming future?

Target Audience who can be benefited from this Extracorporeal Membrane Oxygenation (ECMO) Devices Market Report Study:

• Extracorporeal membrane oxygenation (ECMO) device product providers
• Research organizations and consulting companies
• Extracorporeal membrane oxygenation (ECMO) devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in extracorporeal membrane oxygenation (ECMO) devices
• Various End-users who want to know more about the extracorporeal membrane oxygenation (ECMO) devices market and the latest technological developments in the extracorporeal membrane oxygenation (ECMO) devices market.

Frequently Asked Questions for the Extracorporeal Membrane Oxygenation (ECMO) Devices Market:

1. What are extracorporeal membrane oxygenation (ECMO) devices?

• Extracorporeal membrane oxygenation (ECMO), also known as extracorporeal life support (ECLS), is an extracorporeal technique of providing prolonged cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequate amount of gas exchange or perfusion to sustain life.

2. What is the market for global extracorporeal membrane oxygenation (ECMO) devices?

• The global extracorporeal membrane oxygenation (ECMO) devices market is estimated to grow at a CAGR of 4.1% during the forecast period from 2023 to 2028.

3. What are the drivers for the global extracorporeal membrane oxygenation (ECMO) devices market?

• The demand for extracorporeal membrane oxygenation (ECMO) devices is primarily being heightened by the rising incidence of cardiopulmonary disease and respiratory failure, increasing adoption rate of extracorporeal membrane oxygenation machine (ECMO), increasing number of hospitals offering ECMO services, increasing geriatric population base, and rising number of awareness programs among others, thereby contribute to the overall growth of the extracorporeal membrane oxygenation (ECMO) devices market during the forecast period from 2023-2028.

4. Who are the key players operating in the global extracorporeal membrane oxygenation (ECMO) devices market?

• Some of the key market players operating in the extracorporeal membrane oxygenation (ECMO) devices market include Getinge Group, Medtronic, LivaNova PLC, XENIOS AG, Terumo Corporation, MicroPort Scientific Corporation, NIPRO Corporation, OriGen Biomedical, Inc., EUROSETS S.r.l., Alung Technologies, Inc., Medos Medizintechnik AG, Abiomed, Novalung, Senko Medical Instrument Manufacturing Co. Ltd., Braile Biomedica Ltd., Sorin, Thoratec Corporation, MAQUET Holding B.V. & Co. KG., Tianjin Medical, SHANDONG WEGO NEW LIFE MEDICAL DEVICES CO., LTD., and others.

5. Which region has the highest share in the extracorporeal membrane oxygenation (ECMO) devices market?

• North America is expected to dominate the overall extracorporeal membrane oxygenation (ECMO) devices market during the forecast period from 2023-2028. Factors such as the increasing prevalence of cardiovascular and respiratory diseases, technological advancements in ECMO technology, increased adoption of ECMO systems, government support for quality healthcare, high purchasing power parity, and adoption of advanced technologies of extracorporeal membrane oxygenation (ECMO) devices among others will positively impact the North American extracorporeal membrane oxygenation (ECMO) devices market.

Table of Contents

1. Extracorporeal Membrane Oxygenation (ECMO) Devices Market Report Introduction

2. Extracorporeal Membrane Oxygenation (ECMO) Devices Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Extracorporeal Membrane Oxygenation (ECMO) Devices Market Key Factors Analysis

• 4.1. Extracorporeal Membrane Oxygenation (ECMO) Devices Market Drivers
  • 4.1.1. Increasing incidence of coronary heart and respiratory disease
  • 4.1.2. Increasing number of hospitals offering ECMO services
  • 4.1.3. Growing geriatric population
• 4.2. Extracorporeal Membrane Oxygenation (ECMO) Devices Market Restraints and Challenges
  • 4.2.1. Complications associated with ECMO machines, such as infections, technical failure, and bleeding
  • 4.2.2. Stringent regulatory approvals of the device
• 4.3. Extracorporeal Membrane Oxygenation (ECMO) Devices Market Opportunities
  • 4.3.1. Increasing adoption rate of ECMO machines owing to the increasing awareness
  • 4.3.2. Increasing technological advancements leading to the development of small-size and potable ECMO

5. Extracorporeal Membrane Oxygenation (ECMO) Devices Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. Extracorporeal Membrane Oxygenation (ECMO) Devices Market Layout

• 6.1. By Machine Modality
  • 6.1.1. Veno-arterial
  • 6.1.2. Veno-venous
  • 6.1.3. Arterio-venous
• 6.2. By Patient Type
  • 6.2.1. Pediatric
  • 6.2.2. Adult
• 6.3. By Application
  • 6.3.1. Respiratory
  • 6.3.2. Cardiac
  • 6.3.3. Others
• 6.4. By Geography
  • 6.4.1. North America Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.1.1. United States Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.1.2. Canada Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.1.3. Mexico Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
  • 6.4.2. Europe Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.2.1. France Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.2.2. Germany Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.2.3. United Kingdom Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.2.4. Italy Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.2.5. Spain Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.2.6. Rest of Europe Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
  • 6.4.3. Asia-Pacific Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.3.1. China Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.3.2. Japan Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.3.3. India Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.3.4. Australia Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.3.5. South Korea Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.3.6. Rest of the Asia-Pacific Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
  • 6.4.4. Rest of the World (RoW) Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.4.1. Middle East Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.4.2. Africa Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)
    • 6.4.4.3. South America Extracorporeal Membrane Oxygenation (ECMO) Devices Market Size in USD million (2020-2028)

7. Extracorporeal Membrane Oxygenation (ECMO) Devices Market Company and Product Profiles

• 7.1. Getinge Group
  • 7.1.1. Company Overview
  • 7.1.2. Company Snapshot
  • 7.1.3. Financial Overview
  • 7.1.4. Product Listing
  • 7.1.5. Entropy
• 7.2. Medtronic
  • 7.2.1. Company Overview
  • 7.2.2. Company Snapshot
  • 7.2.3. Financial Overview
  • 7.2.4. Product Listing
  • 7.2.5. Entropy
• 7.3. LivaNova PLC
  • 7.3.1. Company Overview
  • 7.3.2. Company Snapshot
  • 7.3.3. Financial Overview
  • 7.3.4. Product Listing
  • 7.3.5. Entropy
• 7.4. XENIOS AG
  • 7.4.1. Company Overview
  • 7.4.2. Company Snapshot
  • 7.4.3. Financial Overview
  • 7.4.4. Product Listing
  • 7.4.5. Entropy
• 7.5. Terumo Corporation
  • 7.5.1. Company Overview
  • 7.5.2. Company Snapshot
  • 7.5.3. Financial Overview
  • 7.5.4. Product Listing
  • 7.5.5. Entropy
• 7.6. MicroPort Scientific Corporation
  • 7.6.1. Company Overview
  • 7.6.2. Company Snapshot
  • 7.6.3. Financial Overview
  • 7.6.4. Product Listing
  • 7.6.5. Entropy
• 7.7. NIPRO Corporation
  • 7.7.1. Company Overview
  • 7.7.2. Company Snapshot
  • 7.7.3. Financial Overview
  • 7.7.4. Product Listing
  • 7.7.5. Entropy
• 7.8. OriGen Biomedical, Inc.
  • 7.8.1. Company Overview
  • 7.8.2. Company Snapshot
  • 7.8.3. Financial Overview
  • 7.8.4. Product Listing
  • 7.8.5. Entropy
• 7.9. EUROSETS S.r.l.
  • 7.9.1. Company Overview
  • 7.9.2. Company Snapshot
  • 7.9.3. Financial Overview
  • 7.9.4. Product Listing
  • 7.9.5. Entropy
• 7.10. ALung Technologies, Inc.
  • 7.10.1. Company Overview
  • 7.10.2. Company Snapshot
  • 7.10.3. Financial Overview
  • 7.10.4. Product Listing
  • 7.10.5. Entropy
• 7.11. Medos Medizintechnik AG
  • 7.11.1. Company Overview
  • 7.11.2. Company Snapshot
  • 7.11.3. Financial Overview
  • 7.11.4. Product Listing
  • 7.11.5. Entropy
• 7.12. Abiomed
  • 7.12.1. Company Overview
  • 7.12.2. Company Snapshot
  • 7.12.3. Financial Overview
  • 7.12.4. Product Listing
  • 7.12.5. Entropy
• 7.13. Novalung
  • 7.13.1. Company Overview
  • 7.13.2. Company Snapshot
  • 7.13.3. Financial Overview
  • 7.13.4. Product Listing
  • 7.13.5. Entropy
• 7.14. Senko Medical Instrument Manufacturing Co. Ltd.
  • 7.14.1. Company Overview
  • 7.14.2. Company Snapshot
  • 7.14.3. Financial Overview
  • 7.14.4. Product Listing
  • 7.14.5. Entropy
• 7.15. Braile Biomedica Ltd.
  • 7.15.1. Company Overview
  • 7.15.2. Company Snapshot
  • 7.15.3. Financial Overview
  • 7.15.4. Product Listing
  • 7.15.5. Entropy
• 7.16. Sorin
  • 7.16.1. Company Overview
  • 7.16.2. Company Snapshot
  • 7.16.3. Financial Overview
  • 7.16.4. Product Listing
  • 7.16.5. Entropy
• 7.17. Thoratec Corporation
  • 7.17.1. Company Overview
  • 7.17.2. Company Snapshot
  • 7.17.3. Financial Overview
  • 7.17.4. Product Listing
  • 7.17.5. Entropy
• 7.18. MAQUET Holding B.V. & Co. KG.
  • 7.18.1. Company Overview
  • 7.18.2. Company Snapshot
  • 7.18.3. Financial Overview
  • 7.18.4. Product Listing
  • 7.18.5. Entropy
• 7.19. Tianjin Medical
  • 7.19.1. Company Overview
  • 7.19.2. Company Snapshot
  • 7.19.3. Financial Overview
  • 7.19.4. Product Listing
  • 7.19.5. Entropy
• 7.20. SHANDONG WEGO NEW LIFE MEDICAL DEVICES CO., LTD.
  • 7.20.1. Company Overview
  • 7.20.2. Company Snapshot
  • 7.20.3. Financial Overview
  • 7.20.4. Product Listing
  • 7.20.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us